Columbia Care (NEO:CCHW,OTC Pink:COLXF) announced the opening of 20 medical cannabis dispensaries in Florida last Thursday (July 5).

The company expects to have all 20 dispensaries either open or under development in the state by the end of 2019.

The first of the company’s new dispensaries in Florida will be its 4,000 square foot Gainesville location set to open on July 16. Columbia Care CEO Nicholas Vita said in a press release that the rapid growth of cannabis providers and patients in Florida makes the state a prime location.


Cannabis - Will The Fortune 500 Join The Party?

Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!

“Since acquiring our Florida license in 2018, Columbia Care has been quietly assembling its portfolio of dispensaries and building the requisite infrastructure to support the pace of growth that has made the State such a strategic market,” said Vita.

The Gainesville facility will offer Columbia Care’s tinctures, capsules and vaporization devices for medical use. The company also intends to make its in-house medical cannabis brands available in tablet and topical form by the end of the year.

Analyst Matt Bottomley, director of equity research at Canaccord Genuity, has spoken highly of Florida as one of the growing cannabis markets in the US.

Haywood Securities analyst Neal Gilmer shares that sentiment. In a 2018 report on the cannabis market in the US, Gilmer wrote that, while Florida is in the early stages of cannabis adoption, “we believe (it) will continue to support strong growth metrics as the medical program continues to evolve.”

Cannabis legalization has faced obstacles in the state. Despite a majority of Floridians — over 70 percent — voting for a constitutional amendment that would allow the use of cannabis for medical conditions in 2016, then-Governor Rick Scott signed a ban on smoking medical cannabis that was enacted in 2017.

Earlier this year, Florida’s current governor, Ron DeSantis, signed legislation to overturn the ban.

While recreational use is still illegal in the state, the recent legalization of smoking medical cannabis in Florida has made it an attractive market for multi-state operators (MSOs) like Columbia Care.

Other MSOs in Florida have also taken note of the state’s quickly growing medical cannabis market.


Cannabis - Will The Fortune 500 Join The Party?

Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!

Cresco Labs (CSE:CL,OTCQX:CRLBF), a US cannabis company, made its entrance into Florida’s market with its agreement to acquire the ownership interests or assets of VidaCann, one of Florida’s largest providers of medical cannabis, earlier this year. Cresco Labs opened up its 12th VidaCann-branded medical marijuana dispensary in Florida last month.

In its 2018 year-end financial report, released earlier this year, Curaleaf Holdings (CSE:CURA,OTCQX:CURLF) credited a boost in its revenue to its expansions in Florida and New York, as well as acquisitions in Arizona and Massachusetts.

Another MSO, Trulieve Cannabis (CSE:TRUL,OTC Pink:TCNNF), saw a jump in its share price in March when it began to sell smokable medical cannabis products in Florida, becoming the first company in the state to sell “whole-flower smokable cannabis,” according to a press release.

In a recent update from the Florida Office of Medical Marijuana Use, it was reported that there are currently 142 dispensary locations across Florida. Trulieve has the largest number of dispensaries with 30 locations, while Curaleaf and VidCann have 25 and 12 locations, respectively.

According to Statista, medical cannabis sales in Florida will be valued at about US$2.5 billion by 2025.

Shares of Columbia Care opened at C$5.87 Wednesday (July 10) and closed at C$5.61. Since its announcement on July 5, the company’s share price has dipped 16 percent from C$6.69.

Don’t forget to follow us @INN_Cannabis for real-time updates!

Securities Disclosure: I, Danielle Edwards, hold no direct investment interest in any company mentioned in this article.


Cannabis - Will The Fortune 500 Join The Party?

Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!

A middling Canadian cannabis producer announced an executive turnover plan this week after receiving a critical investor letter in September.

Meanwhile, a Canadian exchange-traded fund (ETF) company released lists of new additions to both of its cannabis funds as part of its quarterly rebalancing.

Keep reading... Show less
  • The Cannabis Derivatives are derived from Avicanna’s cultivation and extraction infrastructure in Santa Marta, Colombia designed to supply partner companies and the manufacture of Avicanna’s own finished products.

Avicanna Inc. (” Avicanna ” or the ” Company “) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce that, through its majority owned Colombian subsidiary, Santa Marta Golden Hemp S.A.S. (“ SMGH ”), it has completed a commercial exports of CBD Isolate and CBD full spectrum psychoactive cannabis resin (the “ Cannabis Derivatives ”) to a leading Chilean homeopathic and naturopathic pharmaceutical company.

The Cannabis Derivatives, branded as Aureus™, are cultivated, extracted, and manufactured by SMGH. In addition, for Avicanna’s global input needs, SMGH also supplies other pharmaceutical and cosmetics companies with cannabinoids including CBD, THC, and rare cannabinoids such as CBG in addition to supplying global cultivation companies with standardized and feminized seeds. This new export to Chile is a recurring order and part of on-going relationship with an established homeopathic Chilean company.

Keep reading... Show less

Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX:WEED, NASDAQ:CGC) will release its financial results for the second quarter fiscal year 2022 ended September 30, 2021 before financial markets open on November 5, 2021 .

Keep reading... Show less

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco Labs” or “the Company”), a vertically integrated multistate operator and the number one U.S. wholesaler of branded cannabis products, announced today the opening of a new Sunnyside dispensary in Wyomissing, Pennsylvania. Wyomissing will be Cresco Labs’ fifth dispensary in Pennsylvania and 38 th nationwide.

This press release features multimedia. View the full release here:

Keep reading... Show less

The world of cannabis consumption is set to change radically, thanks in large part to the advancement of state-of-the-art research on the plant itself.

Medical cannabis products have already allowed many new users to discover the plant’s potential, but decisive research will help build a foundation for more sophisticated medical offerings.

Keep reading... Show less